CR20150418A - Compuestos de tetrahidropirrolotiazina - Google Patents

Compuestos de tetrahidropirrolotiazina

Info

Publication number
CR20150418A
CR20150418A CR20150418A CR20150418A CR20150418A CR 20150418 A CR20150418 A CR 20150418A CR 20150418 A CR20150418 A CR 20150418A CR 20150418 A CR20150418 A CR 20150418A CR 20150418 A CR20150418 A CR 20150418A
Authority
CR
Costa Rica
Prior art keywords
tetrahydropirrolotiazine
compounds
compound
formula
provides
Prior art date
Application number
CR20150418A
Other languages
English (en)
Inventor
Steven James Green
Dustin James Mergott
Brian Morgan Watson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Memory Pharm Corp filed Critical Lilly Co Eli
Publication of CR20150418A publication Critical patent/CR20150418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula I; en donde R es H o F; y A es; o una sal del mismo farmacéuticamente aceptable.
CR20150418A 2013-03-12 2015-08-14 Compuestos de tetrahidropirrolotiazina CR20150418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12
PCT/US2014/020070 WO2014143579A1 (en) 2013-03-12 2014-03-04 Tetrahydropyrrolothiazine compounds

Publications (1)

Publication Number Publication Date
CR20150418A true CR20150418A (es) 2015-09-16

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150418A CR20150418A (es) 2013-03-12 2015-08-14 Compuestos de tetrahidropirrolotiazina

Country Status (37)

Country Link
US (3) US8841293B1 (es)
EP (1) EP2970336B1 (es)
JP (1) JP6095844B2 (es)
KR (1) KR101688761B1 (es)
CN (1) CN105026404B (es)
AP (1) AP2015008713A0 (es)
AR (1) AR094918A1 (es)
BR (1) BR112015018738A8 (es)
CA (1) CA2898500C (es)
CL (1) CL2015002529A1 (es)
CR (1) CR20150418A (es)
CY (1) CY1119585T1 (es)
DK (1) DK2970336T3 (es)
EA (1) EA026006B1 (es)
ES (1) ES2653421T3 (es)
HR (1) HRP20171851T1 (es)
HU (1) HUE037487T2 (es)
IL (1) IL240903B (es)
JO (1) JO3317B1 (es)
LT (1) LT2970336T (es)
MA (1) MA38390B1 (es)
ME (1) ME02910B (es)
MX (1) MX2015012628A (es)
MY (1) MY180083A (es)
NO (1) NO3039297T3 (es)
NZ (1) NZ712207A (es)
PE (1) PE20151542A1 (es)
PH (1) PH12015502031A1 (es)
PL (1) PL2970336T3 (es)
PT (1) PT2970336T (es)
RS (1) RS56645B1 (es)
SG (1) SG11201507499XA (es)
SI (1) SI2970336T1 (es)
TN (1) TN2015000340A1 (es)
TW (1) TWI593692B (es)
UA (1) UA112941C2 (es)
WO (1) WO2014143579A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
CA2886507C (en) 2012-10-26 2016-09-20 Eli Lilly And Company Bace inhibitors
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
TWI570127B (zh) 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
TWI574969B (zh) 2015-01-30 2017-03-21 美國禮來大藥廠 甲苯磺酸鹽
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗-N3pGlu類澱粉β肽抗體及其用途
MX388697B (es) 2016-12-15 2025-03-20 Amgen Inc Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX386618B (es) 2016-12-15 2025-03-19 Amgen Inc Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.
MX387729B (es) 2016-12-15 2025-03-18 Amgen Inc Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.
AU2017376445B2 (en) * 2016-12-15 2021-09-30 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
AU2017376441B2 (en) 2016-12-15 2021-10-14 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
AU2003219955A1 (en) * 2002-03-22 2003-10-13 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
ES2537898T3 (es) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BRPI0906962B8 (pt) * 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
TW201302763A (zh) 2011-05-24 2013-01-16 必治妥美雅史谷比公司 用於減少β-類澱粉產生之化合物
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
CN105026404A (zh) 2015-11-04
MY180083A (en) 2020-11-20
HUE037487T2 (hu) 2018-08-28
EA201591491A1 (ru) 2016-01-29
KR101688761B1 (ko) 2016-12-21
PL2970336T3 (pl) 2018-03-30
AU2014228351A1 (en) 2015-09-17
CY1119585T1 (el) 2018-03-07
LT2970336T (lt) 2018-01-10
JP2016512252A (ja) 2016-04-25
HRP20171851T1 (hr) 2018-01-12
DK2970336T3 (da) 2017-11-13
JP6095844B2 (ja) 2017-03-15
US20140350245A1 (en) 2014-11-27
RS56645B1 (sr) 2018-03-30
TW201520217A (zh) 2015-06-01
US8841293B1 (en) 2014-09-23
PE20151542A1 (es) 2015-10-28
CL2015002529A1 (es) 2016-03-28
JO3317B1 (ar) 2019-03-13
KR20150119070A (ko) 2015-10-23
HK1212694A1 (en) 2016-06-17
US20140275044A1 (en) 2014-09-18
BR112015018738A2 (pt) 2017-07-18
AP2015008713A0 (en) 2015-09-30
SI2970336T1 (sl) 2017-11-30
ME02910B (me) 2018-04-20
TWI593692B (zh) 2017-08-01
EP2970336B1 (en) 2017-10-04
CA2898500C (en) 2017-11-14
IL240903B (en) 2018-12-31
WO2014143579A1 (en) 2014-09-18
NZ712207A (en) 2019-09-27
MA38390A1 (fr) 2018-08-31
MA38390B1 (fr) 2020-01-31
EA026006B1 (ru) 2017-02-28
PH12015502031B1 (en) 2016-01-18
IL240903A0 (en) 2015-10-29
EP2970336A1 (en) 2016-01-20
BR112015018738A8 (pt) 2018-01-23
TN2015000340A1 (en) 2017-01-03
CN105026404B (zh) 2016-11-23
ES2653421T3 (es) 2018-02-07
US20150157641A1 (en) 2015-06-11
CA2898500A1 (en) 2014-09-18
PH12015502031A1 (en) 2016-01-18
PT2970336T (pt) 2017-12-21
NO3039297T3 (es) 2018-03-10
SG11201507499XA (en) 2015-10-29
AR094918A1 (es) 2015-09-09
MX2015012628A (es) 2016-07-07
US8987254B2 (en) 2015-03-24
UA112941C2 (uk) 2016-11-10

Similar Documents

Publication Publication Date Title
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2015015450A (es) Inhibidores de histona desacetilasa novedosos.
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
IL245314A0 (en) Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
ECSP17054980A (es) Inhibidores selectivos de bace1
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201690894A1 (ru) Феноксиэтилы
AR095097A1 (es) Compuestos de fenoxietoxi
EA201592183A1 (ru) Ингибиторы bace
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
DOP2014000250A (es) Nuevos compuestos de pirazol
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR124083A2 (es) Nuevo inhibidor de sglt1